Abbott India Ltd SHARE PRICE [LIVE]
Open: | |
High: | |
Low: |
MKT Cap: | |
52-wk High: | |
52-wk Low: |
Prev close: | |
P/E: | |
Div yield: |
Fundamental analysis
What is not working for the company?
What is working for the company?
Name | Dec 22 | Sep 22 |
---|---|---|
Promoters (Change:0.00) | 74.99% | 74.99% |
FIIs (Change:-0.00) | 0.2% | 0.2% |
Mutual Funds (Change:0.74) | 6.41% | 5.67% |
Insurance Companies (Change:-0.20) | 1.84% | 2.04% |
Other DIIs (Change:-0.01) | 0.14% | 0.15% |
Non Institution (Change:-0.53) | 16.42% | 16.95% |
Similar Stocks
Return Calculator
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in Abbott India Ltd
Months ago
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
ABBOTINDIA News
Frequently Asked Questions
What is the Share price of ABBOTT INDIA LTD. (ABBOTINDIA)?
Can I buy ABBOTT INDIA LTD. (ABBOTINDIA) shares?
How do I buy ABBOTT INDIA LTD. (ABBOTINDIA) from Angel One?
- Direct investment: You can buy ABBOTT INDIA LTD. (ABBOTINDIA) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to ABBOTT INDIA LTD. (ABBOTINDIA) shares.
In which sector do ABBOTT INDIA LTD. (ABBOTINDIA) belong?
Is Abbott India a Debt free Company?
Yes, Abbott India is a debt free company.
What is the main business of Abbott India?
The main business of Abbott India is to offer high-quality medicines in therapeutic categories, including women’s health, cardiology, primary care, gastroenterology, and metabolic disorders.
Who are the promoters of Abbott India?
The primary promoters of Abbott India are Abbott Capital India Limited, Abbott Healthcare Products Limited, and British Colloids Limited.
What are the peers of Abbott India?
The top 5 peers of Abbott India are GlaxoSmithKline Pharmaceuticals Ltd., Pfizer Ltd, Sanofi India Ltd, AstraZeneca Pharma India Ltd. and Procter & Gamble Health Ltd.
About ABBOTINDIA
Today's live share price for Abbott India Ltd is NSE: ₹ 21,278.25, BSE: ₹ 21,182.45 with a current market capitalization of .
Abbott India Ltd is one of the largest MNC pharma company operating in India. The Company is engaged in the discovery, development, manufacture and marketing of pharmaceutical, diagnostic, nutritional and hospital products. They are having their presence in both OTC drugs and formulations. Their manufacturing facilities are located at Verna in Goa. The company's global products include Brufen, Prothiaden, Thyronorm and Leptos. The company has four divisions. The Primary Care division markets products in the areas of pain management and gastroenterology. The Specialty Care-Methabolics and Urology division provides solutions in the areas of thyroid, obesity, diabetes and benign prostatic hyperplasia. The Specialty Care-Neuroscience division has a varied portfolio with specialty products in neurology and psychiatric segments. Hospital Care offers products in the field of anesthesiology and neonatology, such as Forane, Sevorane and Survanta. Abbott India Ltd was originally incorporated on August 22, 1944 as Boots Pure Drug Company (India) Ltd. The company name was changed to The Boots Company (India) Ltd on November 1, 1971, thereafter to Boots Pharmaceuticals Ltd on January 1, 1991. In October 31, 1995 the name was changed to Knoll Pharmaceuticals Ltd, and in July 1, 2002, they got their present name Abbott India Ltd. In the year 2002, the company sold their Jejuri Undertakings together with assets and liabilities as a going concern. In the year 2003, the company's wholly owned subsidiary company, Lenbrook Pharmaceuticals Ltd was amalgamated with the company. In the year 2004, the company started the production of Capsules with the capacity of 27 Millions Nos. In the year 2005, they further increased the capacity to 56 Million Nos. Also, they started a new project of producing Nutritional Products with the installed capacity of 600 Tonnes. In the year 2006, the company increased the production capacity of Tablets by 236 Million Nos to 686 Million Nos. In the year 2008, they further increased the production capacity of Tablets by 769 million Nos to 1455 million Nos. They launched Digene Total, buffered pantoprazole tablet for quick and sustained antacid action and Brugel a novel formulation for sprains and strains. Also, they launched Thyronorm 150, Digene Sugar Free Tablet and Gel during the year. The company acquired Solvay Pharmaceuticals, pursuant to which Solvay became a part of Abbott's global Pharmaceutical Products Group.
Read more